Liposarcoma clinical trials
The registry lists 144 studies for Liposarcoma across more than 10 countries. 37 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 57
- Recruiting
- 29
- Terminated
- 17
- Active, not recruiting
- 15
- Withdrawn
- 9
- Status unknown
- 9
Phase
- Phase 2
- 83
- Phase 1
- 46
- Phase 3
- 14
- Early Phase 1
- 2
Where
- United States
- 99
- France
- 19
- Canada
- 18
- United Kingdom
- 13
- Germany
- 13
- Spain
- 11
Who runs them
National Cancer Institute (NCI) (13) · Memorial Sloan Kettering Cancer Center (8) · Fred Hutchinson Cancer Center (6) · Baylor College of Medicine (4) · M.D. Anderson Cancer Center (3) · Boehringer Ingelheim (3) · OHSU Knight Cancer Institute (3) · Maria Sklodowska-Curie National Research Institute of Oncology (3)
Studies
Recruiting first, then most recently updated. Showing 50 of 144 — search for more.
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingNCT06422806Phase 33 countries
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingNCT06025747Phase 11 country
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingNCT06843967Phase 1/21 country
- Doxorubicin With or Without DT-7012 in Advanced Soft Tissue SarcomaNot yet recruitingNCT07802652Phase 21 country
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaRecruitingNCT04031677Phase 315 countries
- Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06578624Phase 1/21 country
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingNCT05711615Phase 11 country
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsRecruitingNCT06541262Phase 1/22 countries
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingNCT06389799Phase 22 countries
- STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected SarcomasRecruitingNCT06975293Phase 1/21 country
- A Phase 3 Study of Ersodetug in Patients With Tumor HyperinsulinismRecruitingNCT06881992Phase 35 countries
- Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsRecruitingNCT04715191Phase 11 country
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaNot yet recruitingNCT07741877Phase 2
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/21 country
- A Study of Pembrolizumab in People With Ultra-Rare SarcomasRecruitingNCT07089992Phase 21 country
- Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal LiposarcomaRecruitingNCT073777478 countries
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingNCT06498648Phase 1/21 country
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsRecruitingNCT06789172Phase 13 countries
- Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma PatientsRecruitingNCT074329321 country
- Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T CellsRecruitingNCT07148050Phase 11 country
- Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue SarcomaRecruitingNCT07169344Phase 21 country
- Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.RecruitingNCT07173972Phase 21 country
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingNCT06849986Phase 21 country
- Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorAvailableNCT07262970
- Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid TumorsNot yet recruitingNCT07224568Phase 11 country
- Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T CellsRecruitingNCT06198296Phase 11 country
- MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaRecruitingNCT06277154Phase 21 country
- APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsRecruitingNCT04785196Phase 1/21 country
- Identification of a New Blood Biomarker for the Diagnosis and Prognosis of LiposarcomasRecruitingNCT04224064Not applicable1 country
- EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial SarcomaNot yet recruitingNCT06748872Phase 11 country
- First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingNCT06694324Phase 21 country
- Genomic Risk in Retroperitoneal SarcomaRecruitingNCT064368461 country
- A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsRecruitingNCT05094804Phase 1/21 country
- Investigating Engagement Patterns and Participation Trends Among Liposarcoma PatientsNot yet recruitingNCT060390461 country
- A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Enrolling by invitationNCT05266196Phase 1/21 country
- Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma PatientsRecruitingNCT02275286Phase 1/23 countries
- International Prospective Registry on Local Treatment Approaches in MLSRecruitingNCT046992921 country
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive, not recruitingNCT02923778Phase 22 countries
- Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaActive, not recruitingNCT05694871Phase 21 country
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryActive, not recruitingNCT03307616Phase 21 country
- Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingNCT04438824Phase 21 country
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsActive, not recruitingNCT04557449Phase 28 countries
- BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaActive, not recruitingNCT06414434Phase 11 country
- Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingNCT04668300Phase 21 country
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/33 countries
- APX005M and Doxorubicin in Advanced SarcomaCompletedNCT03719430Phase 21 country
- Study of Abemaciclib in Dedifferentiated LiposarcomaActive, not recruitingNCT02846987Phase 21 country
- Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 21 country
- Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryActive, not recruitingNCT03361436Phase 11 country
- Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid TumorsActive, not recruitingNCT05103631Phase 11 country